Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood ; 120(1): 112-21, 2012 Jul 05.
Artículo en Inglés | MEDLINE | ID: mdl-22649103

RESUMEN

Dendritic cells (DCs) are essential in inducing adaptive immune responses against bacteria by expressing cytokines that skew T-cell responses toward protective Th17 cells. Although it is widely recognized that induction of these cytokines by DCs involves activation of multiple receptors, it is still incompletely characterized which combination of receptors specifically skews Th17-cell responses. Here we have identified a novel role for FcγRIIa in promoting human Th17 cells. Activation of DCs by bacteria opsonized by serum IgG strongly promoted Th17 responses, which was FcγRIIa-dependent and coincided with enhanced production of selected cytokines by DCs, including Th17-promoting IL-1ß and IL-23. Notably, FcγRIIa stimulation on DCs did not induce cytokine production when stimulated individually, but selectively amplified cytokine responses through synergy with TLR2, 4, or 5. Importantly, this synergy is mediated at 2 different levels. First, TLR-FcγRIIa costimulation strongly increased transcription of pro-IL-1ß and IL-23p19. Second, FcγRIIa triggering induced activation of caspase-1, which cleaves pro-IL-1ß into its bioactive form and thereby enhanced IL-1ß secretion. Taken together, these data identified cross-talk between TLRs and FcγRIIa as a novel mechanism by which DCs promote protective effector Th17-cell responses against bacteria.


Asunto(s)
Infecciones Bacterianas/inmunología , Células Dendríticas/inmunología , Inmunoglobulina G/inmunología , Receptores de IgG/inmunología , Células Th17/inmunología , Receptores Toll-Like/inmunología , Inmunidad Adaptativa/inmunología , Comunicación Celular/inmunología , Citocinas/inmunología , Citocinas/metabolismo , Células Dendríticas/citología , Células Dendríticas/microbiología , Escherichia coli/inmunología , Infecciones por Escherichia coli/inmunología , Humanos , Ligandos , Macrófagos/citología , Macrófagos/inmunología , Macrófagos/microbiología , Receptor Cross-Talk/inmunología , Infecciones por Salmonella/inmunología , Salmonella typhimurium/inmunología , Infecciones Estafilocócicas/inmunología , Staphylococcus aureus/inmunología , Staphylococcus epidermidis/inmunología , Células Th17/citología , Células Th17/microbiología
2.
Blood ; 118(23): 6107-14, 2011 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-21926348

RESUMEN

IL-17-producing CD4(+) T helper (Th17) cells are important for immunity against extracellular pathogens and in autoimmune diseases. The factors that drive Th17 development in human remain a matter of debate. Here we show that, compared with classic CD28 costimulation, alternative costimulation via the CD5 or CD6 lymphocyte receptors forms a superior pathway for human Th17-priming. In the presence of the Th17-promoting cytokines IL-1ß, IL-6, IL-23, and transforming growth factor-ß (TGF-ß), CD5 costimulation induces more Th17 cells that produce higher amounts of IL-17, which is preceded by prolonged activation of signal transducer and activator of transcription 3 (STAT3), a key regulator in Th17 differentiation, and enhanced levels of the IL-17-associated transcription factor retinoid-related orphan receptor-γt (ROR-γt). Strikingly, these Th17-promoting signals critically depend on CD5-induced elevation of IL-23 receptor (IL-23R) expression. The present data favor the novel concept that alternative costimulation via CD5, rather than classic costimulation via CD28, primes naive T cells for stable Th17 development through promoting the expression of IL-23R.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Antígenos CD5/inmunología , Receptores de Interleucina/inmunología , Células Th17/inmunología , Adulto , Antígenos CD28/inmunología , Antígenos CD28/metabolismo , Complejo CD3/inmunología , Complejo CD3/metabolismo , Linfocitos T CD4-Positivos/citología , Antígenos CD5/metabolismo , Diferenciación Celular/inmunología , Expresión Génica/inmunología , Humanos , Interleucina-17/genética , Interleucina-17/inmunología , Interleucina-17/metabolismo , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/genética , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/inmunología , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Receptores de Interleucina/genética , Factor de Transcripción STAT3/inmunología , Factor de Transcripción STAT3/metabolismo , Transducción de Señal/inmunología , Células Th17/citología , Transcripción Genética/inmunología
3.
J Histochem Cytochem ; 54(12): 1425-35, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16957167

RESUMEN

During germinal center (GC) reactions, B-lymphocytes with high-affinity B-cell receptors are selected. Regulation of apoptosis is a key process in selecting such wanted B-cells and in eliminating B-cells with unwanted specificities. In this paper, we show that apoptosis in human GC B-cells involves lysosomal destabilization, which is strictly controlled by caspase-8 activity, but not by caspase-9 activity. Ligation of CD40 provides resistance to lysosomal destabilization. Experimental lysosomal rupture by the lysosomotropic drug O-methyl-l-serine dodecylamide hydrochloride (MSDH) induces apoptosis in GC B-cells, including phosphatidyl serine exposure, mitochondrial inactivation, and DNA fragmentation. These apoptotic features occur in the absence of caspase-3 activity. Follicular dendritic cells (FDCs) protect binding B-lymphocytes from lysosomal destabilization, in both the absence and the presence of MSDH. Our study demonstrates that lysosomal leakage induces apoptosis of GC B-cells in a caspase-3-independent manner and that high-affinity binding to FDCsprevents lysosomal leakage and apoptosis in GC B-cells.


Asunto(s)
Apoptosis/fisiología , Linfocitos B/metabolismo , Centro Germinal/metabolismo , Lisosomas/metabolismo , Amidas/farmacología , Apoptosis/efectos de los fármacos , Linfocitos B/citología , Linfocitos B/efectos de los fármacos , Antígenos CD40/metabolismo , Caspasa 3/metabolismo , Caspasa 8/metabolismo , Células Cultivadas , Fragmentación del ADN/efectos de los fármacos , Células Dendríticas Foliculares/metabolismo , Centro Germinal/citología , Humanos , Lisosomas/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Fosfatidilserinas/metabolismo , Serina/análogos & derivados , Serina/farmacología
4.
Nat Commun ; 5: 5444, 2014 Nov 13.
Artículo en Inglés | MEDLINE | ID: mdl-25392121

RESUMEN

M2 macrophages suppress inflammation in numerous disorders, including tumour formation, infection and obesity. However, the exact role of M2 macrophages in the context of several other diseases is still largely undefined. We here show that human M2 macrophages promote inflammation instead of suppressing inflammation on simultaneous exposure to complexed IgG (c-IgG) and TLR ligands, as occurs in the context of diseases such as rheumatoid arthritis (RA). c-IgG-TLR ligand co-stimulation of M2 macrophages selectively amplifies production of pro-inflammatory cytokines TNF-α, IL-1ß and IL-6 and promotes Th17 responses, which all play a critical role in RA pathology. Induction of pro-inflammatory cytokines on c-IgG co-stimulation mainly depends on Fc gamma receptor IIa (FcγRIIa), which selectively amplifies cytokine gene transcription and induces caspase-1 activation. These data indicate that FcγR-TLR cross-talk may be targeted for treatment to attenuate inflammation in RA, by restoring the anti-inflammatory function of M2 macrophages.


Asunto(s)
Inflamación/fisiopatología , Interleucina-1beta/fisiología , Interleucina-6/fisiología , Macrófagos/fisiología , Receptor Cross-Talk/fisiología , Receptores de IgG/fisiología , Factor de Necrosis Tumoral alfa/fisiología , Caspasa 1/metabolismo , Activación Enzimática/fisiología , Regulación de la Expresión Génica/fisiología , Humanos , Interleucina-1beta/biosíntesis , Interleucina-6/biosíntesis , Macrófagos/metabolismo , Receptores de IgG/metabolismo , Células Th17/fisiología , Factor de Necrosis Tumoral alfa/biosíntesis
5.
Clin Exp Metastasis ; 26(3): 171-8, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19067186

RESUMEN

Cancer progression is facilitated by blood coagulation. Anticoagulants, such as Hirudin and low molecular weight heparins (LMWHs), reduce metastasis mainly by inhibition of thrombin formation and L- and P-selectin-mediated cell-cell adhesion. It is unknown whether the effects are dependent on cancer cell type. The effects of anticoagulants on tumor development of K1735 and B16 melanoma cells and CT26 colon cancer cells were investigated in mouse lung. Tumor load was determined noninvasively each week up to day 21 in all experiments using bioluminescence imaging. Effects of anticoagulants on tumor development of the three cell lines were correlated with the fibrin/fibrinogen content in the tumors, expression of tissue factor (TF), protease activated receptor (PAR)-1 and -4 and CD24, a ligand of L- and P-selectins. Hirudin inhibited tumor development of B16 cells in lungs completely but did not affect tumor growth of K1735 and CT26 cells. Low molecular weight heparin did not have an effect on K1735 melanoma tumor growth either. TF and PAR-4 expression was similar in the three cell lines. PAR-1 and CD24 were hardly expressed by K1735, whereas CT26 cells expressed low levels and B16 high levels of PAR-1 and CD24. Fibrin content of the tumors was not affected by LMWH. It is concluded that effects of anticoagulants are dependent on cancer cell type and are correlated with their CD24 and PAR-1 expression.


Asunto(s)
Anticoagulantes/farmacología , Neoplasias Pulmonares/patología , Animales , Anticoagulantes/uso terapéutico , Coagulación Sanguínea/efectos de los fármacos , Antígeno CD24/metabolismo , Línea Celular Tumoral , Fibrina/metabolismo , Fibrinógeno/metabolismo , Heparina de Bajo-Peso-Molecular/farmacología , Heparina de Bajo-Peso-Molecular/uso terapéutico , Hirudinas/farmacología , Neoplasias Pulmonares/irrigación sanguínea , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/secundario , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de Neoplasias , Selectina-P/metabolismo , Receptor PAR-1/metabolismo , Tromboplastina/biosíntesis , Trasplante Heterólogo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA